top of page

Effects of Psychedelic Mushrooms

Psychedelic mushrooms, also known as "magic mushrooms," contain the psychoactive compound psilocybin. When consumed, psilocybin is converted into psilocin, which is a hallucinogen that can produce a variety of effects, including altered perceptions, hallucinations, and changes in mood and thought.

The effects of psychedelic mushrooms can vary depending on the dose, individual physiology, and the setting in which they are consumed. However, some of the most common effects include:

  • Hallucinations: This is one of the most well-known effects of psychedelic mushrooms. Users might see colors and shapes that aren't there, or objects might appear to move or warp. Some people report experiencing "synesthesia," a blending of senses, such as "hearing" colors.

  • Altered perception of time: Many users report that their sense of time is altered, with minutes seeming to pass like hours, or vice versa.

  • Euphoria: Users often report intense feelings of happiness, joy, and wellbeing. This is often accompanied by fits of laughter.

  • Deep introspection: People often experience deep introspective thoughts and feelings. This can lead to a sense of enlightenment or the feeling of having uncovered profound truths about oneself or the universe.

  • Physical sensations: Physical effects can include an increased heart rate, dilated pupils, restlessness or relaxation, dry mouth, and in some cases, nausea.

As with any substance, it is important to approach the use of psychedelic mushrooms with caution. If you are considering using psychedelic mushrooms, it is important to do your research and understand the potential risks and benefits. You should also make sure to consume them in a safe and supportive environment.


1. Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of general psychiatry, 68(1), 71-78.

2. Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., ... & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry, 3(7), 619-627.

3. Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Reviews Neuroscience, 11(9), 642-651.

4. Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011). Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology, 218(4), 649-665.

5. Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264-355.

V. Taybron is a passionate blog writer with a flair for storytelling and a love for words. With a knack for engaging readers through captivating content, V. Taybron creates blog posts that inform, entertain, and inspire. Join V. Taybron on a journey of exploration and discovery through their thought-provoking articles.


bottom of page